PS
DTIL icon

Principal Securities’s Precision BioSciences DTIL Stock Holding History

Principal Securities’s Portfolio DTIL Stock Details DTIL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-69
Closed -$290 – 3758
2025
Q2 		$290 Buy
+69
New +$340 ﹤0.01% 3563

Other funds holding DTIL

BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Principal Securities's DTIL Position: Q3 2025 in Review

Principal Securities sold out of Precision BioSciences (DTIL) in Q3 2025, closing a stake of 69 shares — an estimated $290 sold.

Principal Securities first reported a position in DTIL in Q2 2025 and held it in 1 quarter. The position peaked at $290 in Q2 2025. 56 funds tracked by Wall St. Rank hold DTIL as of Q3 2025.

  • Principal Securities reported no remaining Precision BioSciences position as of Q3 2025 after selling out during the quarter.
  • Principal Securities sold 69 Precision BioSciences shares in Q3 2025, an estimated $290.
  • Principal Securities first reported a position in Precision BioSciences in Q2 2025 and held it in 1 quarter.
  • Principal Securities's Precision BioSciences position peaked at $290 in Q2 2025.
  • 56 funds tracked by Wall St. Rank held Precision BioSciences as of Q3 2025.

Based on Principal Securities's 13F filing for Q3 2025, filed 12 Nov 2025.